FDA Grants Orphan Drug Status to (Z)-Endoxifen for Duchenne Muscular Dystrophy
Atossa Therapeutics receives FDA orphan drug designation for (Z)-endoxifen to treat Duchenne muscular dystrophy, a rare genetic muscle-wasting disease.
/ 1661 items
#XY↓
ImmunityBio Stock Soars 100% in 2026 on Blockbuster Drug Sales
ImmunityBio shares surge with 10-day winning streak as ANKTIVA cancer drug revenue jumps 700% to $113M. Saudi approval and analyst targets signal more upside ahead.
Texas Pharmacy Sues Eli Lilly and Novo Nordisk Over GLP-1 Weight-Loss Drug Access
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
FDA Delays Decisions on Lilly's Obesity Pill and Other Fast-Track Drug Reviews
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Boston Scientific to Acquire Penumbra in $14.5 Billion Deal
Boston Scientific announces acquisition of Penumbra for $14.5B, expanding into blood clot removal and neurovascular treatments to address cardiovascular diseases.